ESC 365 - Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial

HFA Premium Access

Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial

Session: Chronic heart failure - treatment 3

Topic: Pharmacotherapy

Speaker: Doctor T. Kondo (Glasgow, GB)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Toru Kondo

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

4 more presentations in this session

Efficacy of dapagliflozin according to heart rate in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER

Speaker: Doctor T. Kondo (Glasgow, GB)

Calcium channel blocker and outcomes in patients with heart failure and mildly reduced or preserved ejection fraction

Speaker: Doctor S. Matsumoto (Tokyo, JP)

Medium term improvement in left ventricular systolic function following CRT pacemaker implantation indicates additional defibrillator component may not be necessary

Speaker: Doctor H. Shabbir (Blackburn, GB)

Left bundle branch block cardiomyopathy: an intriguing and defiant entity from diagnosis to treatment

Speaker: Ms C. Oliveira (Porto, PT)

Access the full session

Chronic heart failure - treatment 3

Speakers: Doctor T. Kondo, Doctor T. Kondo, Doctor S. Matsumoto, Doctor H. Shabbir, Ms C. Oliveira

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources